BusinessPostCorner.com
No Result
View All Result
Tuesday, June 3, 2025
  • Home
  • Business
  • Finance
  • Accounting
  • Tax
  • Management
  • Marketing
  • Crypto News
  • Human Resources
BusinessPostCorner.com
  • Home
  • Business
  • Finance
  • Accounting
  • Tax
  • Management
  • Marketing
  • Crypto News
  • Human Resources
No Result
View All Result
BusinessPostCorner.com
No Result
View All Result

Novo Nordisk’s obesity drug cuts risk of death by 18%, trial data shows

November 11, 2023
in Finance
Reading Time: 2 mins read
A A
0
Novo Nordisk’s obesity drug cuts risk of death by 18%, trial data shows
ShareShareShareShareShare

Unlock the Editor’s Digest for free

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.

Novo Nordisk’s weight-loss drug Wegovy cut the risk of death by 18 per cent in a trial that the Danish pharmaceutical company hopes will convince more health systems and insurers to pay for the treatment. 

Martin Holst Lange, executive vice-president of development at Novo Nordisk, said new data showed in more detail how the drug was “incredibly powerful” in tackling cardiovascular risk. 

Lange said that payers would be interested in the impact the drug had on mortality and expensive conditions, pointing to the “quite profound” effect it had in cutting the risk of heart attacks by 28 per cent. 

In August, initial data from the Select trial sent shares in Novo Nordisk up as much as 16 per cent, as investors became excited that the results could win over any health systems and insurers reluctant to cover the new class of weight-loss drugs. Wegovy has a US list price of more than $1,300 a month.

The full data was announced on Saturday at an American Heart Association congress and published in the New England Journal of Medicine. 

The results were published at the end of a week when Eli Lilly received US Food and Drug Administration approval for its obesity treatment Zepbound, which will compete with Wegovy, and AstraZeneca entered the race for a weight-loss pill after a partnership deal with Chinese biotech Eccogene.  

Novo Nordisk’s trial studied more than 17,600 people aged above 45 with obesity who had cardiovascular disease, but not diabetes. About 458 patients taking a placebo died during the trial, compared with 375 people taking Wegovy, representing an 18 per cent reduced risk of death.

There was a 15 per cent decline in the risk of death from cardiovascular causes specifically, though the numbers did not quite meet the bar for statistical significance. 

The paper comes after the preliminary results showed that patients who took Wegovy had a 20 per cent lower chance of suffering a cardiovascular event such as a stroke or heart attack than participants who received a placebo. 

Lange said the trial also showed the drug had an impact on other conditions such as kidney disease. Last month, Novo Nordisk ended a trial designed to monitor the effect of Ozempic, a diabetes drug that contains semaglutide, the same active ingredient as Wegovy, on chronic kidney disease because the early results showed it was likely to be very successful. That data will be published in the next couple of months. 

“I expect to see really, really interesting and exciting data on the impact of semaglutide on chronic kidney disease,” Lange said.

Credit: Source link

ShareTweetSendPinShare
Previous Post

Americans say they have no idea how to tip anymore

Next Post

Oil majors call on Washington and Brussels to intervene in LNG dispute

Next Post
Oil majors call on Washington and Brussels to intervene in LNG dispute

Oil majors call on Washington and Brussels to intervene in LNG dispute

Anthropic CEO warns AI could eliminate half of all entry-level white-collar jobs

Anthropic CEO warns AI could eliminate half of all entry-level white-collar jobs

May 28, 2025
NYC Comptroller Rejects Mayor Adams’s “Bitbond” Proposal as Legally and Fiscally Flawed

NYC Comptroller Rejects Mayor Adams’s “Bitbond” Proposal as Legally and Fiscally Flawed

May 31, 2025
AICPA wants Congress to change tax bill

AICPA wants Congress to change tax bill

May 30, 2025
Michael Saylor’s Strategy Slows Bitcoin Buys as MSTR Premium Shrinks, Says K33

Michael Saylor’s Strategy Slows Bitcoin Buys as MSTR Premium Shrinks, Says K33

May 28, 2025
FTX Recovery Trust Begins B Second Payout to Creditors

FTX Recovery Trust Begins $5B Second Payout to Creditors

May 31, 2025
SEC Challenges ETF Status of Proposed Staked Solana and Ether Funds

SEC Challenges ETF Status of Proposed Staked Solana and Ether Funds

June 1, 2025
BusinessPostCorner.com

BusinessPostCorner.com is an online news portal that aims to share the latest news about following topics: Accounting, Tax, Business, Finance, Crypto, Management, Human resources and Marketing. Feel free to get in touch with us!

Recent News

Texas Congressman Slammed for Delayed Bitcoin Disclosure of 0K Purchases

Texas Congressman Slammed for Delayed Bitcoin Disclosure of $500K Purchases

June 3, 2025
BlackRock removed from Texas blacklist after climate policy rollback

BlackRock removed from Texas blacklist after climate policy rollback

June 3, 2025

Our Newsletter!

Loading
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • DMCA

© 2023 businesspostcorner.com - All Rights Reserved!

No Result
View All Result
  • Home
  • Business
  • Finance
  • Accounting
  • Tax
  • Management
  • Marketing
  • Crypto News
  • Human Resources

© 2023 businesspostcorner.com - All Rights Reserved!